{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:57:56Z","timestamp":1787162276395,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      Febuxostat, a novel non\u2010purine selective inhibitor of xanthine oxidase, has been identified as a potential alternative to allopurinol in patients with hyperuricemia. The purpose of this study was to compare the urate\u2010lowering (\n                      <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>\n                      ) efficacy and safety of daily febuxostat and allopurinol in\n                      <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                      hinese gout patients with hyperuricemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Gout patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0512) with serum uric acid (s\n                      <jats:styled-content style=\"fixed-case\">UA<\/jats:styled-content>\n                      ) concentrations of at least 8.0\u00a0mg\/dL were randomized to receive daily febuxostat 40\u00a0mg or 80\u00a0mg or allopurinol 300\u00a0mg for 28\u00a0weeks. Prophylaxis against gout flares with meloxicam or colchicine was provided during weeks 1 through 8. The primary endpoint was the percentage of subjects achieving a s\n                      <jats:styled-content style=\"fixed-case\">UA<\/jats:styled-content>\n                      concentration of &lt;6.0\u00a0mg\/dL at the last three monthly measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary endpoint was reached in 44.77% of patients receiving 80\u00a0mg of febuxostat, 27.33% of those receiving 40\u00a0mg of febuxostat, and 23.84% of those receiving allopurinol. The\n                      <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>\n                      efficacy in the febuxostat 80\u00a0mg group was higher than in the allopurinol (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001) and febuxostat 40\u00a0mg (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0008) groups. The\n                      <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>\n                      efficacy of the febuxostat 40\u00a0mg group was statistically non\u2010inferior to that of the allopurinol group. No significant change in the number of tophi was observed during the final visit relative to baseline in each treatment group. The rate of gout flares requiring treatment from weeks 9 through 28 and the incidence of adverse events was similar among treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>\n                      efficacy of daily febuxostat 80\u00a0mg was greater than that of febuxostat 40\u00a0mg and allopurinol 300\u00a0mg, which exhibited comparable\n                      <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>\n                      efficacy. Safety of febuxostat and allopurinol was comparable at the doses tested.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.12266","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T07:24:03Z","timestamp":1390893843000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["An allopurinol\u2010controlled, multicenter, randomized, double\u2010blind, parallel between\u2010group, comparative study of febuxostat in\n                    <scp>C<\/scp>\n                    hinese patients with gout and hyperuricemia"],"prefix":"10.1111","volume":"17","author":[{"given":"Xinfang","family":"Huang","sequence":"first","affiliation":[{"name":"Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[{"name":"Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Changhai Hospital Affiliated to Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Affiliated to Fudan University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfu","family":"Li","sequence":"additional","affiliation":[{"name":"Qilu Hospital Affiliated to Shandong University Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central\u2010South University Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Huaxi Hospital Affiliated to Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpei","family":"Li","sequence":"additional","affiliation":[{"name":"Anhui Provincial Hospital Hefei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Xijing Hospital Fourth Military Medical University Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Southern Medical University South Hospital Huangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Harbin Medical University Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbin","family":"Huang","sequence":"additional","affiliation":[{"name":"Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Hospital Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunde","family":"Bao","sequence":"additional","affiliation":[{"name":"Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200205000-00015"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.545"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780080449"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(88)90127-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(83)90209-0"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113972"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117479"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.1993.03510030102044","article-title":"Uric acid. A risk factor for coronary heart disease","volume":"270","author":"Frohlich ED","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20065"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835d951e"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.6.855"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00003"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030733"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199813030-00006"},{"key":"e_1_2_9_19_1","first-page":"925","article-title":"Gout and hyperuricemia","volume":"59","author":"Harris MD","year":"1999","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d352f"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d351d"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12266","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T04:51:31Z","timestamp":1695531091000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/1756-185X.12266"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12266","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,28]]},"assertion":[{"value":"2014-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}